WALTHAM -
Inducement Equity Incentive Plan, or the Inducement Plan. The stock option was granted as an inducement material to the new employee's becoming an employee of ImmunoGen in accordance with Nasdaq Listing Rule 5635(4).
The Inducement Plan is used exclusively for the grant of equity awards to individuals who were not previously employees of ImmunoGen (or following a bona fide period of non-employment), as an inducement material to such individual's entering into employment with ImmunoGen, pursuant to Rule 5635(4) of the Nasdaq Listing Rules.
The option has an exercise price of
ABOUT IMMUNOGEN
ImmunoGen is developing the next generation of antibody-drug conjugates to improve outcomes for cancer patients. By generating targeted therapies with enhanced anti-tumor activity and favorable tolerability profiles, we aim to disrupt the progression of cancer and offer our patients more good days. We call this our commitment to 'target a better now.'
Contact:
Tel: 781-895-0600
Email: courtney.okonek@immunogen.com
(C) 2020 Electronic News Publishing, source